NEWPORT BEACH, Calif. – jCyte, Inc., a private biotechnology company dedicated to improving the lives of patients with retinal degenerative diseases, announced the continued expansion of the company’s executive management team with the appointment of Adrian Morris as Chief Development Officer. Mr. Morris brings to jCyte over three decades of...
Latest News
NEWPORT BEACH, Calif. – jCyte, Inc., a biotech company dedicated to improving the lives of patients with retinal degenerative diseases, today announced the further expansion of the company’s executive management team with the appointment of John Sholar as General Counsel. Mr. Sholar brings to jCyte more than 20 years of...
NEWPORT BEACH, Calif. — jCyte, Inc., a pioneering biotechnology company dedicated to preserving and restoring vision in patients with retinitis pigmentosa (RP) and other degenerative retinal disorders, is pleased to announce the successful outcome of its pre-phase 3 Type B meeting with the US Food and Drug Administration (FDA) held...
TORONTO, Canada – JDRF and Sanofi Canada are announcing a partnership aimed at amplifying awareness around type 1 diabetes (T1D), a chronic autoimmune condition, and the role screening could play in the early detection of this disease. Nationally, the number of individuals diagnosed with T1D is growing at an estimated...
PHILADELPHIA – A protein related to aggressive cancers can actually improve the efficacy of gemcitabine at treating pancreatic cancer, according to a Priority Report in Cancer Research, published by researchers at Thomas Jefferson University. The protein, called Hu antigen R (HuR), is a stress response protein found in the cytoplasm...
SHANGHAI, China — Jemincare, a leading pharmaceutical company from China, announced that its wholly owned subsidiary company, Shanghai Jemincare Pharmaceutical Co., Ltd., recently received 6 approvals of clinical trials for its innovative drugs in the field of cancer, kidney and anti-infectious diseases, including 4 approvals from National Medical Products Administration...
SHANGHAI, China — In another milestone since the implementation of CAR-T therapy at Jiahui, the first myeloma patient treated with CAR-T at Jiahui International Hospital was recently discharged two weeks after infusion. The foreign patient was first diagnosed with multiple myeloma in 2008. Despite multiple treatments including chemotherapy, immunotherapy, target...
Changchun, China – Scientists have identified a new organelle in liver cells called the mitochondria-lysosome-related organelle (MLRO). This discovery could improve our understanding of chronic liver diseases like alcohol-associated liver disease (ALD) and metabolic dysfunction-associated fatty liver disease (MAFLD). Mitochondria are essential components of cells, often called the “powerhouses” because...
Changchun, China – While heavy drinking is a well-established risk factor for liver cancer, the specific mechanisms by which alcohol contributes to A-HCC remain unclear. This insightful review, published in Hepatology, provides a comprehensive summary of the pathogenesis, heterogeneity, preclinical approaches, epigenetic and genetic profiles of A-HCC. Compared to other types of...
Washington, D.C. – With ever-increasing life expectancy comes the challenge of treating age-related disorders such as osteoporosis. Although there are effective drugs for treating this metabolic bone disease, they can be expensive and have side effects, limiting their availability to some people. In the search for alternative drug candidates, researchers...